Hidradenitis

6 trials 2 recruiting MedDRA PT
6 Registered trials
2 Recruiting
4 Unique sponsors
3 Unique IMPs
6 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune) 1 substance
BTK inhibitor 1 substance
Monoclonal antibody (humanized) 1 substance
Phase III: 4 Phase II: 1 Phase I: 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

4 trials
  • Novartis Pharma AG Commercial
    REMIBRUTINIB
    2024-513266-19-00 10 countries 2025 n=250
    Ended
  • Novartis Pharma AG Commercial
    REMIBRUTINIB
    2024-513282-39-00 9 countries 2025 n=205
    Ended
  • Novartis Pharma AG Commercial
    REMIBRUTINIB
    2025-523259-72-00 12 countries n=307
    Pending
  • UCB Biopharma Commercial
    BIMEKIZUMAB
    2023-505323-31-00 2 countries 2025 n=18
    Recruiting

Phase II

1 trial
  • Sanofi-Aventis Research & Development Commercial
    AMLITELIMAB
    2023-505803-22-00 7 countries 2024 n=49
    Ended

Phase I

1 trial
  • Sanofi-Aventis Recherche & Developpement Commercial
    IMP not specified
    2026-525333-22-00 1 country 2026 n=134
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 3 Phase III 0
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase I 1
Sanofi-Aventis Research & Development Commercial 1 Phase II 0
UCB Biopharma Commercial 1 Phase III 1
New trials by year
2024
1
2025
3
2026
1
← All indication landscapes